Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared some papers on LinkedIn:
“Hot off the press
Pleased to share my new commentary: “Matching hallmarks of cancer complexity with N-of-1 precision oncology” Cell Press Journal MED
A viewpoint on the latest iteration of Doug Hanahan’s Hallmarks of Cancer framework and the i-PREDICT trial, and what they mean together for Precision Medicine.
What is Precision Oncology ‘s E=MC2
Free Cell Press Link for 50 days.”
Title: Matching hallmarks of cancer complexity with N-of-1 precision oncology
Author: Vivek Subbiah.
Other articles featuring Vivek Subbiah on OncoDaily.